Additionally, and in the same direction, other NK-cell-inhibitory receptors—such as T-cell immunoglobulin and mucin domain 3 (TIM-3), and lymphocyte activation gene-3 (LAG3)—are now being investigated, alone or in combination with other therapeutic approaches, for the immunotherapy of a wide spectrum of cancers [51], including GBM (NCT03493932, NCT02658981, NCT03961971). Here, HAVCR2 is linked to cancer.